Cash and cash equivalents of $75.6 million as of March 31, 2025, expected to fund operations into the second half of 2027
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Promising Potential of QTORIN in Addressing Unmet Needs in Vascular Anomalies: A Buy Recommendation for Palvella Therapeutics
- Palvella Therapeutics granted U.S patent for QTORIN Rapamycin
- Palvella Therapeutics announces data on QTORIN rapamycin
- Palvella Therapeutics initiated with a Buy at Chardan
- Palvella Therapeutics price target raised to $53 from $39 at Canaccord